94.22
1.22 (1.31%)
| Previous Close | 93.00 |
| Open | 93.04 |
| Volume | 1,864,565 |
| Avg. Volume (3M) | 1,906,277 |
| Market Cap | 18,751,143,936 |
| Price / Earnings (TTM) | 14.70 |
| Price / Earnings (Forward) | 12.02 |
| Price / Sales | 3.63 |
| Price / Book | 3.58 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | 0.48% |
| Operating Margin (TTM) | 20.65% |
| Diluted EPS (TTM) | 0.200 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | -6.70% |
| Total Debt/Equity (MRQ) | 1.18% |
| Current Ratio (MRQ) | 2.04 |
| Operating Cash Flow (TTM) | 382.59 M |
| Levered Free Cash Flow (TTM) | 618.05 M |
| Return on Assets (TTM) | 2.04% |
| Return on Equity (TTM) | 0.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Incyte Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.01% |
| % Held by Institutions | 100.65% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 135.00 (HC Wainwright & Co., 43.28%) | Buy |
| Median | 110.00 (16.75%) | |
| Low | 92.00 (RBC Capital, -2.36%) | Hold |
| Average | 111.89 (18.75%) | |
| Total | 5 Buy, 4 Hold | |
| Avg. Price @ Call | 101.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Mar 2026 | 135.00 (43.28%) | Buy | 97.10 |
| 11 Feb 2026 | 135.00 (43.28%) | Buy | 98.84 | |
| Evercore ISI Group | 05 Mar 2026 | 110.00 (16.75%) | Hold | 97.33 |
| Barclays | 18 Feb 2026 | 117.00 (24.18%) | Buy | 102.99 |
| 04 Feb 2026 | 116.00 (23.12%) | Buy | 102.60 | |
| RBC Capital | 11 Feb 2026 | 92.00 (-2.36%) | Hold | 98.84 |
| Stifel | 11 Feb 2026 | 120.00 (27.36%) | Buy | 98.84 |
| Wells Fargo | 11 Feb 2026 | 101.00 (7.20%) | Hold | 98.84 |
| 20 Jan 2026 | 107.00 (13.56%) | Hold | 102.62 | |
| Piper Sandler | 06 Feb 2026 | 110.00 (16.75%) | Buy | 108.39 |
| TD Cowen | 13 Jan 2026 | 128.00 (35.85%) | Buy | 103.43 |
| Morgan Stanley | 06 Jan 2026 | 94.00 (-0.23%) | Hold | 106.66 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Jan 2026 | Announcement | Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) |
| 27 Jan 2026 | Announcement | Incyte to Report Fourth Quarter and Year-End 2025 Financial Results |
| 05 Jan 2026 | Announcement | Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |